Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

29-09-2020 | ESMO 2020 | Conference coverage | Video

monarchE and PALLAS: A tale of two CDK4/6 inhibitors

George Sledge Jr speculates on the reasons for the contrasting results of the monarchE and PALLAS trials of adjuvant abemaciclib and palbociclib, respectively, in hormone receptor-positive, early-stage breast cancer (5:46).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript
Image Credits